Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

Overview

Journal Ann Neurol

Specialty Neurology

Date 2024 Jul 4

PMID 38963256

Authors

Matthew R Brier

Suzanne E Schindler

Amber Salter

Dana Perantie

Nicole Shelley

Bradley Judge

Sarah Keefe

Kristopher M Kirmess

Philip B Verghese

Kevin E Yarasheski

Venky Venkatesh

Cyrus A Raji

Brian A Gordon

Randall J Bateman

John C Morris

Robert T Naismith

David M Holtzman

Tammie L S Benzinger

Anne H Cross

Affiliations

Soon will be listed here.

Abstract

The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453-459.

Citing Articles

More than microglia: myeloid cells and biomarkers in neurodegeneration.

Kodosaki E, Bell R, Sogorb-Esteve A, Wiltshire K, Zetterberg H, Heslegrave A Front Neurosci. 2024; 18:1499458.

PMID: 39544911 PMC: 11560917. DOI: 10.3389/fnins.2024.1499458.

References

Mielke M, Dage J, Frank R, Algeciras-Schimnich A, Knopman D, Lowe V . Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022; 28(7):1398-1405. PMC: 9329262. DOI: 10.1038/s41591-022-01822-2. View

Rissman R, Langford O, Raman R, Donohue M, Abdel-Latif S, Meyer M . Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimers Dement. 2023; 20(2):1214-1224. PMC: 10916957. DOI: 10.1002/alz.13542. View

Meyer M, Kirmess K, Eastwood S, Wente-Roth T, Irvin F, Holubasch M . Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 2024; 20(5):3179-3192. PMC: 11095426. DOI: 10.1002/alz.13764. View

Barthelemy N, Salvado G, Schindler S, He Y, Janelidze S, Collij L . Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024; 30(4):1085-1095. PMC: 11031399. DOI: 10.1038/s41591-024-02869-z. View

Schindler S, Atri A . The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer's disease diagnostic revolution. Nat Aging. 2023; 3(5):460-462. PMC: 10720501. DOI: 10.1038/s43587-023-00400-6. View

Hittle M, Culpepper W, Langer-Gould A, Marrie R, Cutter G, Kaye W . Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. JAMA Neurol. 2023; 80(7):693-701. PMC: 10186207. DOI: 10.1001/jamaneurol.2023.1135. View

Landau S, Ward T, Murphy A, Iaccarino L, Harrison T, La Joie R . Quantification of amyloid beta and tau PET without a structural MRI. Alzheimers Dement. 2022; 19(2):444-455. DOI: 10.1002/alz.12668. View

Luczynski P, Laule C, Hsiung G, Moore G, Tremlett H . Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. Mult Scler Relat Disord. 2018; 27:232-238. DOI: 10.1016/j.msard.2018.10.109. View

Ontaneda D, Sati P, Raza P, Kilbane M, Gombos E, Alvarez E . Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. Neuroimage Clin. 2021; 32:102834. PMC: 8482479. DOI: 10.1016/j.nicl.2021.102834. View

10.

Zeydan B, Lowe V, Reichard R, Przybelski S, Lesnick T, Schwarz C . Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Ann Neurol. 2020; 87(4):556-567. PMC: 7078013. DOI: 10.1002/ana.25684. View

11.

Solomon A . Diagnosis, Differential Diagnosis, and Misdiagnosis of Multiple Sclerosis. Continuum (Minneap Minn). 2019; 25(3):611-635. DOI: 10.1212/CON.0000000000000728. View

12.

McDade E . Alzheimer Disease. Continuum (Minneap Minn). 2022; 28(3):648-675. DOI: 10.1212/CON.0000000000001131. View

13.

Marrie R, Fisk J, Fitzgerald K, Kowalec K, Maxwell C, Rotstein D . Etiology, effects and management of comorbidities in multiple sclerosis: recent advances. Front Immunol. 2023; 14:1197195. PMC: 10266935. DOI: 10.3389/fimmu.2023.1197195. View

14.

West T, Kirmess K, Meyer M, Holubasch M, Knapik S, Hu Y . A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener. 2021; 16(1):30. PMC: 8088704. DOI: 10.1186/s13024-021-00451-6. View

15.

Ostolaza A, Corroza J, Ayuso T . Multiple sclerosis and aging: comorbidity and treatment challenges. Mult Scler Relat Disord. 2021; 50:102815. DOI: 10.1016/j.msard.2021.102815. View

16.

Dal Bianco A, Bradl M, Frischer J, Kutzelnigg A, Jellinger K, Lassmann H . Multiple sclerosis and Alzheimer's disease. Ann Neurol. 2007; 63(2):174-83. DOI: 10.1002/ana.21240. View

17.

Koenig L, Day G, Salter A, Keefe S, Marple L, Long J . Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. Neuroimage Clin. 2020; 26:102248. PMC: 7182765. DOI: 10.1016/j.nicl.2020.102248. View

18.

Benedict R, Amato M, DeLuca J, Geurts J . Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020; 19(10):860-871. PMC: 10011205. DOI: 10.1016/S1474-4422(20)30277-5. View

19.

Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A . Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape. Neuron. 2023; 111(18):2781-2799. PMC: 10720399. DOI: 10.1016/j.neuron.2023.05.017. View